NAD+ vs MOTS-c
NAD+, MOTS-c, and SS-31 (Elamipretide) all target mitochondrial function, but through fundamentally different mechanisms. NAD+ (nicotinamide adenine dinucleotide) is a coenzyme -- not technically a peptide -- that fuels critical mitochondrial enzymes and sirtuins. MOTS-c is a mitochondrial-derived peptide encoded within the mitochondrial genome that activates AMPK and mimics the metabolic benefits of exercise. SS-31 is a synthetic tetrapeptide that binds cardiolipin in the inner mitochondrial membrane, stabilizing cristae structure and reducing reactive oxygen species (ROS). Together, these three compounds are sometimes referred to as the "mitochondrial trifecta" in longevity research communities, each addressing a different layer of mitochondrial health.
Side-by-Side Comparison
| Category | NAD+ | MOTS-c |
|---|---|---|
| Mechanism of action | NAD+ is an essential coenzyme for oxidative phosphorylation in the electron transport chain (Complex I). It also activates sirtuins (SIRT1-7), which regulate mitochondrial biogenesis, DNA repair, and metabolic homeostasis. NAD+ additionally fuels PARPs (poly-ADP-ribose polymerases) for DNA damage repair. Levels decline 40-60% with age, contributing to mitochondrial dysfunction. | MOTS-c is a 16-amino-acid peptide encoded by the 12S rRNA gene in mitochondrial DNA. It activates AMPK (the cellular energy sensor), enhances glucose uptake in skeletal muscle, improves fatty acid oxidation, and regulates the folate-methionine cycle. Functions as an endogenous exercise mimetic -- circulating levels increase during physical activity and decline with age. |
| Primary research area | Age-related metabolic decline, neurodegeneration, cardiovascular aging, and DNA repair. Precursor supplementation (NMN, NR) studied for NAD+ repletion. Clinical interest in Alzheimer's, heart failure, and general longevity. | Metabolic syndrome, obesity, insulin resistance, and exercise physiology. Studied as a potential therapeutic for type 2 diabetes and age-related metabolic dysfunction. Emerging research in osteoporosis and immune function. |
| Evidence level | Extensive preclinical data on NAD+ biology. Human clinical trials for NMN and NR supplementation show NAD+ level increases but mixed results on functional outcomes. Phase I/II trials ongoing for multiple age-related conditions. NAD+ IV infusion protocols used clinically (off-label) for addiction, chronic fatigue, and neurodegeneration. Not FDA-approved as a therapeutic. | Primarily preclinical. Foundational studies by Changhan David Lee's lab at USC demonstrated MOTS-c's role in metabolic regulation and exercise response. Animal studies show improvement in obesity, insulin sensitivity, and age-related metabolic decline. A first-in-human Phase I trial has been conducted. Not FDA-approved. |
| Administration route | IV infusion (250-750 mg sessions), subcutaneous injection, or oral supplementation via precursors (NMN at 250-1000 mg/day or NR at 300-1000 mg/day). IV provides the most direct NAD+ elevation but is expensive and requires clinical administration. | Subcutaneous injection in research settings. No established oral bioavailability. Endogenous levels are modulated by exercise -- regular physical activity naturally increases MOTS-c production. |
| Typical research dosing | IV: 250-750 mg infused over 2-4 hours, 1-2 times weekly. SubQ: 50-100 mg daily (NAD+ direct). Oral precursors: NMN 500-1000 mg/day or NR 300-600 mg/day. Cycling is common: 4-8 weeks on, 2-4 weeks off. | SubQ: 5-10 mg 3-5 times weekly. Research protocols vary widely as optimal human dosing has not been established. Typically cycled 4-8 weeks on, 2-4 weeks off. |
| Key studies/evidence | Yoshino et al. (2021) -- NMN improved muscle insulin sensitivity in prediabetic women (Science). Martens et al. (2018) -- NR improved blood pressure and arterial compliance. Imai & Guarente (2014) -- foundational NAD+ and sirtuin biology review (Trends in Cell Biology). Multiple ongoing NIH-funded trials on NAD+ repletion in aging. | Lee et al. (2015) -- MOTS-c discovery paper establishing metabolic regulatory role (Cell Metabolism). Kim et al. (2018) -- MOTS-c regulates nuclear gene expression via AMPK. Reynolds et al. (2021) -- exercise-induced MOTS-c circulation in humans. D'Souza et al. (2022) -- MOTS-c and skeletal muscle insulin sensitivity. |
Can They Be Stacked?
The "mitochondrial trifecta" stack (NAD+ + SS-31 + MOTS-c) is discussed in longevity research communities as a comprehensive approach to mitochondrial health. The rationale is mechanistically sound: SS-31 protects mitochondrial structure (cardiolipin stabilization), NAD+ fuels mitochondrial enzymes and sirtuins, and MOTS-c optimizes cellular energy utilization via AMPK. No published studies have evaluated this specific three-way combination in humans, but the non-overlapping mechanisms suggest additive rather than redundant effects. Individuals often start with NAD+ repletion (the most established intervention) and layer in SS-31 and MOTS-c based on specific goals.
Verdict
These three compounds address different layers of mitochondrial dysfunction and are more complementary than competitive. SS-31 stabilizes the physical structure of mitochondria by binding cardiolipin in the inner membrane, protecting cristae architecture and reducing electron leak that generates damaging ROS -- this is the structural foundation. NAD+ provides the biochemical fuel that powers Complex I of the electron transport chain and activates sirtuins that regulate mitochondrial biogenesis and quality control -- this is the energetic foundation. MOTS-c activates AMPK-mediated metabolic pathways that improve how cells utilize the energy mitochondria produce, particularly in skeletal muscle -- this is the metabolic optimization layer. For a core mitochondrial support protocol, SS-31 + NAD+ (or NMN/NR) represents the most evidence-backed combination: structural protection paired with energetic repletion. Adding MOTS-c provides additional metabolic flexibility benefits, particularly for individuals dealing with insulin resistance or metabolic syndrome. However, MOTS-c has the least human clinical data of the three, so it remains the most experimental component. None of these are FDA-approved therapeutics (SS-31/Elamipretide has been in Phase III trials for Barth syndrome and is the furthest along in regulatory development).
Disclaimer: This content is for educational purposes only and does not constitute medical advice. Peptides are biologically active compounds that carry risks. Consult a healthcare provider before using any peptides. Many peptides discussed here have limited human clinical data — always verify current research status before making decisions.